CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis

B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer and the prognosis of children with relapsed or therapy refractory disease remains a challenge. Treatment with chimeric antigen receptor-modified T cells targeting the CD19 antigen (CART-19 therapy) has been presented as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fischer, Jeannette, Paret, Claudia, El Malki, Khalifa, Alt, Francesca, Wingerter, Arthur, Neu, Marie A., Kron, Bettina, Russo, Alexandra, Lehmann, Nadine, Roth, Lea, Fehr, Eva-M., Attig, Sebastian, Hohberger, Alexander, Kindler, Thomas, Faber, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424577/
https://www.ncbi.nlm.nih.gov/pubmed/28441264
http://dx.doi.org/10.1097/CJI.0000000000000169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424577/
https://www.ncbi.nlm.nih.gov/pubmed/28441264
http://dx.doi.org/10.1097/CJI.0000000000000169

Ejemplares similares